Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kaken Pharmaceutical’s Artz Expands Market

This article was originally published in PharmAsia News

Executive Summary

Kaken Pharmaceutical estimated a seven percent increase in company business operation profit for the fiscal year ending March 2009. However, Daiwa Securities analysis projected a nine percent increase and predicted stable growth for the company's best selling product Artz amid the current economic downturn. Artz is a viscoelastic supplement injection to replace synovial fluid in osteoarthritic knees. Daiwa cited that the number of the patients for the drug is increasing due to a progressively aging population, and as awareness of the treatment increases among potential patients, the market basis for the drug will also expand. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts